OPKO Health, Inc. (NASDAQ:OPK – Free Report) – Investment analysts at Zacks Research issued their FY2027 earnings estimates for OPKO Health in a research report issued on Thursday, March 20th.

OPKO Health, Inc. has a twelve month low of $0.99 and a twelve month high of $2.04. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -9.47 and a beta of 1.70.

Insiders have been trading these 5 stocks: (($BBY)), (($LVS)), (($GSAT)), (($OPK)) and (($A)). Here is a breakdown of their ...

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics (BRNS – Research Report) today and set a price target of ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

After hours: March 24 at 7:59:56 p.m. EDT Loading Chart for OPK ...

In a regulatory filing, Best Buy (BBY) disclosed that its CFO Matthew Bilunas sells 51K shares of common stock on March 24th in a total ...

Labcorp lists the plant as part of its consumer genetics business and plans to begin eliminating positions in May.

Commerce provider, today announced the financial results for the fiscal year-ended December 31, 2024 which includes the consolidation of the operations of its e-Commerce Operations with ...

March 26, 2025 • As the U.S. health system grapples with new outbreaks and the risk of old diseases making a comeback, we're looking to the past to inform how people in marginalized communities ...